(UAMY) United States Antimony - Overview
Stock: Antimony, Zeolite, Precious Metals, Flame Retardants, Environmental
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 177% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.80 |
| Alpha | 322.97 |
| Character TTM | |
|---|---|
| Beta | 1.254 |
| Beta Downside | 0.370 |
| Drawdowns 3y | |
|---|---|
| Max DD | 74.30% |
| CAGR/Max DD | 2.43 |
Description: UAMY United States Antimony December 31, 2025
United States Antimony Corporation (NYSE MKT: UAMY) manufactures antimony compounds, zeolite products, and recovers precious metals across the United States and Canada, operating through two primary segments: Antimony and Zeolite.
In the Antimony segment, the firm sells antimony oxide for synergistic flame-retardant systems in plastics, rubber, textiles and coatings, antimony trisulfide for ammunition primers, and metallic antimony for bearings, batteries and ordnance. In the Zeolite segment, it offers coarse and fine zeolite for applications ranging from soil amendment and water filtration to catalysts in petroleum refining, solar-energy heat exchangers, and animal litter. The company also processes unrefined and refined gold and silver as by-products.
Key market drivers include the ongoing regulatory push for halogen-free flame retardants, which can pressure demand for antimony-based solutions, and the projected 5-6% CAGR growth in the global zeolite market through 2028, fueled by expanding use in renewable-energy and water-treatment projects. As of the latest quarter, UAMY’s antimony sales accounted for roughly 70% of total revenue, while its cash-flow conversion hovered near 0.8×, reflecting modest operating leverage. For a deeper quantitative dive, the ValueRay platform offers granular financial and operational metrics on UAMY.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -4.94m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -26.28 > 1.0 |
| NWC/Revenue: 77.15% < 20% (prev 114.8%; Δ -37.65% < -1%) |
| CFO/TA -0.06 > 3% & CFO -5.04m > Net Income -4.94m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.4m) vs 12m ago 13.81% < -2% |
| Gross Margin: 25.78% > 18% (prev 0.02%; Δ 2576 % > 0.5%) |
| Asset Turnover: 60.38% > 50% (prev 36.88%; Δ 23.50% > 0%) |
| Interest Coverage Ratio: -10.75 > 6 (EBITDA TTM -4.07m / Interest Expense TTM -526.4k) |
Altman Z'' -6.11
| A: 0.32 (Total Current Assets 31.8m - Total Current Liabilities 6.26m) / Total Assets 79.9m |
| B: -0.57 (Retained Earnings -45.2m / Total Assets 79.9m) |
| C: -0.10 (EBIT TTM -5.66m / Avg Total Assets 54.8m) |
| D: -5.40 (Book Value of Equity -43.9m / Total Liabilities 8.13m) |
| Altman-Z'' Score: -6.11 = D |
Beneish M -2.47
| DSRI: 0.79 (Receivables 1.90m/791.6k, Revenue 33.1m/11.0m) |
| GMI: 0.08 (GM 25.78% / 2.00%) |
| AQI: 1.19 (AQ_t 0.25 / AQ_t-1 0.21) |
| SGI: 3.02 (Revenue 33.1m / 11.0m) |
| TATA: 0.00 (NI -4.94m - CFO -5.04m) / TA 79.9m) |
| Beneish M-Score: -2.47 (Cap -4..+1) = BBB |
What is the price of UAMY shares?
Over the past week, the price has changed by +17.46%, over one month by +23.18%, over three months by +21.95% and over the past year by +362.90%.
Is UAMY a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UAMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.7 | 12.3% |
| Analysts Target Price | 9.7 | 12.3% |
| ValueRay Target Price | 10.3 | 19% |
UAMY Fundamental Data Overview February 03, 2026
P/S = 32.2201
P/B = 16.1816
Revenue TTM = 33.1m USD
EBIT TTM = -5.66m USD
EBITDA TTM = -4.07m USD
Long Term Debt = 93.2k USD (from longTermDebt, last quarter)
Short Term Debt = 164.7k USD (from shortTermDebt, last quarter)
Debt = 265.2k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -18.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.01b USD (1.03b + Debt 265.2k - CCE 19.6m)
Interest Coverage Ratio = -10.75 (Ebit TTM -5.66m / Interest Expense TTM -526.4k)
EV/FCF = -47.24x (Enterprise Value 1.01b / FCF TTM -21.3m)
FCF Yield = -2.12% (FCF TTM -21.3m / Enterprise Value 1.01b)
FCF Margin = -64.41% (FCF TTM -21.3m / Revenue TTM 33.1m)
Net Margin = -14.91% (Net Income TTM -4.94m / Revenue TTM 33.1m)
Gross Margin = 25.78% ((Revenue TTM 33.1m - Cost of Revenue TTM 24.6m) / Revenue TTM)
Gross Margin QoQ = 23.14% (prev 26.96%)
Tobins Q-Ratio = 12.61 (Enterprise Value 1.01b / Total Assets 79.9m)
Interest Expense / Debt = 0.67% (Interest Expense 1779 / Debt 265.2k)
Taxrate = 21.0% (US default 21%)
NOPAT = -4.47m (EBIT -5.66m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.08 (Total Current Assets 31.8m / Total Current Liabilities 6.26m)
Debt / Equity = 0.00 (Debt 265.2k / totalStockholderEquity, last quarter 71.8m)
Debt / EBITDA = 4.44 (negative EBITDA) (Net Debt -18.1m / EBITDA -4.07m)
Debt / FCF = 0.85 (negative FCF - burning cash) (Net Debt -18.1m / FCF TTM -21.3m)
Total Stockholder Equity = 42.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.00% (Net Income -4.94m / Total Assets 79.9m)
RoE = -11.58% (Net Income TTM -4.94m / Total Stockholder Equity 42.6m)
RoCE = -13.25% (EBIT -5.66m / Capital Employed (Equity 42.6m + L.T.Debt 93.2k))
RoIC = -10.42% (negative operating profit) (NOPAT -4.47m / Invested Capital 42.9m)
WACC = 10.54% (E(1.03b)/V(1.03b) * Re(10.54%) + D(265.2k)/V(1.03b) * Rd(0.67%) * (1-Tc(0.21)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.07%
Fair Price DCF = unknown (Cash Flow -21.3m)
EPS Correlation: -42.48 | EPS CAGR: -65.71% | SUE: -4.0 | # QB: 0
Revenue Correlation: 55.89 | Revenue CAGR: 44.88% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.10 | Chg30d=-0.010 | Revisions Net=+0 | Growth EPS=+350.0% | Growth Revenue=+201.4%